Ionis FDA approval a positive for Arrowhead, says H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio believes the FDA approval of Ionis Pharmaceuticals’ (IONS) Tryngolza, an oligonucleotide, for the treatment of familial chylomicronemia syndrome, has positive read-through to Arrowhead’s (ARWR) plozasiran. Based on the “compelling” Phase 3 trial data generated from Arrowhead’s plozasiran, an RNA interference therapeutic targeting apolipoprotein C-III in familial chylomicronemia syndrome, plozasiran should also be approved by the second half of 2025 with a broad label, the analyst tells investors in a research note. Furthermore, with “best-in-class” characteristics on efficacy, quarterly dosing, and side effect profile, H.C. Wainwright believes plozasiran, if approved, is well positioned to become standard-of-care in familial chylomicronemia syndrome. The firm reiterates a Buy rating on the shares with an $80 price target.